Eli and Edythe L. Broad endow the Broad Institute of Harvard and MIT with additional $400 million

Los Angeles-based philanthropists Eli and Edythe Broad today declared the Broad Institute of Harvard and MIT  an unprecedented success as an experiment in science and philanthropy, and announced that they have increased their total gift to the Broad by $400 million to $600 million.  The $400 million will be an endowment to convert the institute — which was originally launched as a 10-year “venture” experiment — into a permanent biomedical research organization aimed at transforming medicine.

The total $600 million commitment is the largest to support biomedical research activity at universities anywhere in the world. The gift also reflects a new model for venture philanthropy, for collaboration among universities, and for doing biomedical science.

The Broad Institute was launched in 2004 — just after the completion of the Human Genome Project (HGP) — with the mission of fulfilling the promise of genomics for medicine and the goal of sustaining the collaborative spirit that propelled the HGP. The institute aimed to bring scientists together to tackle major interdisciplinary problems related to cancer, metabolic diseases, infectious diseases, psychiatric diseases, and other conditions.

Rather than calling a single university home, the Broad Institute was launched as a new kind of research organization spanning the entire Massachusetts Institute of Technology and Harvard communities, including the 17 Harvard-affiliated teaching hospitals. As a result, scientists from the various institutions — and from diverse disciplines, including biology, medicine, chemistry, and computer science — created collaborative teams to tackle problems beyond what any of them could do alone. The Broad Institute was also committed to scientific openness, including rapid and free sharing of data and research tools. Today, more than 1,200 scientists and professional staff from across Harvard and MIT are affiliated with the institute.

Rather than initially endow the new organization, Eli and Edythe Broad decided to take a “venture” approach in 2004. They made a commitment of $100 million to be spent over 10 years — investing in an “experiment” to test whether the new model would dramatically accelerate scientific progress. In late 2005, they doubled their gift to $200 million over 10 years in recognition of the Broad Institute’s early progress. 

Acknowledgment of the power of this model of science has also come from the Stanley Medical Research Institute, which gave $100 million in 2007 to create the Stanley Center for Psychiatric Research at the Broad Institute. The Starr Foundation, the Prostate Cancer Foundation, and the Juvenile Diabetes Research Foundation, among others, have also provided significant funds to support the institute’s collaborative work and groundbreaking advances in a variety of human diseases.

Now, after just four years, Harvard, MIT, and the Broads have declared the experiment a rousing success that should be sustained as a permanent institution. As a result of the Broads’ endowment, the Broad Institute will transition to a permanent nonprofit organization, with both universities continuing to help govern it. The mission and collaborative research by scientists from across Harvard and MIT will continue to be at the heart of the Broad Institute.

“Of all of our philanthropy, the Broad Institute has been the investment that has yielded the greatest returns,” said Eli Broad, founder of The Eli and Edythe Broad Foundation. “This truly is a new way of doing science, and the institute’s unique collaborative model for scientific research has resulted in remarkable accomplishments in a very short period of time. Although this is a large gift — the largest we have ever made — it is only a fraction of what will be needed to unlock the enormous promise of biomedical research at MIT and Harvard. We hope to see this endowment grow to $1 billion through investment and additional gifts, and we are counting on others to step forward as partners in the next phase of this grand experiment. We are convinced that the genomics and biomedical work being conducted here at the world’s leading genomics center by the world’s best and brightest scientists will ultimately lead to the cure and even the prevention of diseases.”

“Eli and Edythe Broad are true visionaries,” said Eric Lander, founding director of the Broad Institute. “They made an enormous bet in 2004. Their bet has paid off more handsomely than any of us imagined. It has unleashed the creative potential of a remarkable community of scientists. And, it has defined a new model for how scientists and institutions can work together.”

“There is no place in the world with as great a concentration of life sciences talent, resources, and vision as Massachusetts,” said Deval Patrick (D), governor of the Commonwealth of Massachusetts. “With this significant endowment of the Broad Institute by Eli and Edythe Broad — and the collaboration and support of the industry, academia, business and government through the Massachusetts Life Sciences Initiative — we are on our way to helping find new cures for diseases, creating new jobs, and positioning ourselves for long-term economic growth.”

In the Broad Institute’s short history, its researchers have already made major contributions to biomedicine. The progress made in the past four years includes the following:

• Cataloging the genetic variation among individuals and populations, which is the critical groundwork for identifying the genetic contribution to common human diseases;

• Identifying scores of new genetic risk factors for diseases such as type 2 diabetes, Crohn’s disease, schizophrenia, bipolar disorder, autism, cardiovascular disease, and a variety of cancers;

• Classifying human cancers by their genomic alterations, rather than by their location in the body;

• Combining the power of genomics and the power of chemical biology to uncover potential new therapeutics for cancer, malaria, and other diseases, as well as novel uses for existing drugs, including a well-known immunosuppressive drug that may treat leukemia;

• Identifying the genomic regulatory controls of stem cell differentiation — research that will accelerate progress in regenerative medicine;

• Harnessing the power of proteomics and genomics to understand how cells generate and use energy and how the process runs amok in a host of diseases;

• Applying genomic tools to key human pathogens, such as malaria and tuberculosis, aimed at transforming how these killers are tracked, diagnosed, and treated;

• Leading efforts, such as The Cancer Genome Atlas, to comprehensively identify the molecular abnormalities that underlie all human cancers; and

• Sequencing the genomes of more than 20 mammals, providing stunning depth to our knowledge of evolution and unlocking the mysteries of the human genome.

“To fully realize the benefits of the genomic sciences, scientific research must transcend the boundaries of disciplines, departments, and even institutions,” said Harvard President Drew Faust. “Through their continued philanthropy, the Broads have made that transcendence possible. I am grateful for their support of this important work and look forward to continuing our partnership with the Broad Institute.”

“Cambridge and Boston are world-renowned for their creative, scientific minds and unrivaled biomedical community, and the Broad Institute is uniquely positioned to realize the full potential of these intellectual resources,” said Susan Hockfield, president of MIT. “We are profoundly grateful to Eli and Edythe Broad for their generosity and vision, and look forward to continuing our many collaborative research efforts through the Broad Institute and defining the future of the field.”